This clinical trial is focused on studying a condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), which is a disease affecting the immune system. The study is evaluating a treatment known as riliprubart, also referred to by its code name SAR445088. Riliprubart is administered as a solution for injection using a pre-filled pen. The main goal of this study is to assess the long-term safety and tolerability of riliprubart in individuals with CIDP.

Participants in this study will receive riliprubart through subcutaneous injections, which means the medication is injected under the skin. The study will monitor participants over an extended period to observe any side effects or adverse events that may occur. Additionally, the study will track the percentage of participants who remain free from relapses and those who show improvement in their condition. Changes in disability scores, grip strength, and muscle strength will also be measured to evaluate the effectiveness of the treatment.

The study is designed to provide valuable information about the long-term use of riliprubart in managing CIDP. By participating in this study, researchers aim to gather data that could help improve treatment options for individuals living with this chronic condition. The study is expected to continue until 2029, allowing for comprehensive observation and analysis of the treatment’s impact over time.